PPARγ罗格列酮对HT-29的生长抑制作用(英文)

Growth inhibition induced by peroxisome proliferator activated receptor gamma ligand rosiglitazone in human colorectal cancer cell line HT-29

PPARγ配体在抗肿瘤中发挥着重要的作用,这些配体具有抗肿瘤、诱导分化和抗血管生成等效果.目的主要是评估PPARγ激动剂罗格列酮对结肠癌细胞株HT-29生长的抑制作用.结果显示,罗格列酮可以有效地抑制体外培养的结肠癌细胞株HT-29的生长及克隆形成,并能抑制HT-29裸鼠移植瘤的生长.与此同时,罗格列酮能够升高PPAR,γp-PPARγ的表达水平.以上结果初步证明罗格列酮在体内外均可抑制结肠癌细胞株HT-29的成长,提示罗格列酮有可能发展成为治疗结肠癌的有效药物.

Peroxisome proliferators-activated receptors （PPARs） ligands play an important role in antitumorigenesis due to their anti-proliferative, pro-differential and anti-angiogenic effects. The aim of this study is to evaluate the effect of PPART ligand rosiglitazone （ROZ） on the growth and proliferation in human colorectal cancer cell line HT- 29. The effect of ROZ on HT -29 cell proliferation were measured by MTF and colony formation assay . DNA and protein synthesis were examined by [ 3 H ] - Thymidine and [ 3 H ] - Leucine incorpora- tion assay respectively. PPART expression was detected by RT -PCR and Western blotting analysis. ROZ inhibited cell proliferation, colony formation and inhibited the tumor growth of HT -29 in immunodeficient mice. Simultaneously, it increased the expression of PPARγ, p - PPARγ. These results indicated that ROZ inhibited growth of HT -29 cells in vitro and in vivo. It suggested that ROZ might be a promising therapeutic agent for colon cancer